

# Yong Song

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893738/publications.pdf>

Version: 2024-02-01

47  
papers

2,489  
citations

567281

15  
h-index

345221

36  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long non-coding RNAs: A new frontier in the study of human diseases. <i>Cancer Letters</i> , 2013, 339, 159-166.	7.2	1,041
2	A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small cell lung cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, E1-E12.	2.7	261
3	The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers. <i>Tumor Biology</i> , 2016, 37, 1437-1444.	1.8	159
4	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	4.4	150
5	The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 9160-9172.	1.8	141
6	Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small cell lung cancer diagnosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 20721-20727.	4.1	118
7	Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 409-415.	2.1	81
8	Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2016, 95, e4608.	1.0	80
9	Post-transcriptional regulation of long noncoding RNAs in cancer. <i>Tumor Biology</i> , 2015, 36, 503-513.	1.8	70
10	Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25558-25575.	1.8	66
11	Long non-coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2184-2198.	3.6	59
12	Long intergenic noncoding RNA 00673 promotes non-small-cell lung cancer metastasis by binding with EZH2 and causing epigenetic silencing of HOXA5. <i>Oncotarget</i> , 2017, 8, 32696-32705.	1.8	51
13	Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 300-9.	2.8	32
14	Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage III lung adenocarcinoma. <i>Thoracic Cancer</i> , 2017, 8, 260-270.	1.9	25
15	Metastasis-associated fibroblasts: an emerging target for metastatic cancer. <i>Biomarker Research</i> , 2021, 9, 47.	6.8	24
16	Blocking SphK1/S1P/S1PR1 Signaling Pathway Alleviates Lung Injury Caused by Sepsis in Acute Ethanol Intoxication Mice. <i>Inflammation</i> , 2021, 44, 2170-2179.	3.8	19
17	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. <i>Translational Lung Cancer Research</i> , 2021, 10, 415-429.	2.8	13
18	Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice. <i>Translational Lung Cancer Research</i> , 2015, 4, 27-35.	2.8	12

#	ARTICLE	IF	CITATIONS
19	Prognostic value of Twist in lung cancer: systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 236-41.	2.8	11
20	The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 792-6.	2.8	11
21	Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. <i>Frontiers in Immunology</i> , 2021, 12, 818492.	4.8	11
22	Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 610-8.	2.8	8
23	<i>MET</i> gene fusions in non-small cell lung cancer (NSCLC) in the Chinese population: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13539-e13539.	1.6	7
24	Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 18-26.	2.8	7
25	F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer. <i>Human Cell</i> , 2022, 35, 260-270.	2.7	6
26	Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis. <i>Lung Cancer</i> , 2018, 125, 43-50.	2.0	4
27	Neutrophil-derived long noncoding RNA IL-7R predicts development of multiple organ dysfunction syndrome in patients with trauma. <i>European Journal of Trauma and Emergency Surgery</i> , 2020, , 1.	1.7	4
28	Prevalence of <i>EGFR</i> gene fusions in a large cohort of Chinese patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e13538-e13538.	1.6	4
29	Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14050-e14050.	1.6	3
30	Diagnostic and therapeutic value of computed tomography guided coil placement after digital subtraction angiography guided video-assisted thoracoscopic surgery resection for solitary pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2015, 4, 598-604.	2.8	3
31	Real-world large-scale study of ERBB2 gene fusions and its response to afatinib in Chinese non-small cell lung cancer (NSCLC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13002-e13002.	1.6	2
32	Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11623-11623.	1.6	1
33	Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13120-e13120.	1.6	1
34	Incidence of FGFR-TACC gene fusions in Chinese non-small cell lung cancer (NSCLC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13001-e13001.	1.6	1
35	Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23138-e23138.	1.6	1
36	A 61-year-old man with cough and white sputum. <i>Translational Lung Cancer Research</i> , 2015, 4, 94-8.	2.8	1

#	ARTICLE	IF	CITATIONS
37	A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients. <i>Translational Lung Cancer Research</i> , 2015, 4, 487-97.	2.8	1
38	Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencingâ€”A multicenter study (Yangtze River Delta Lung Cancer Cooperation) Tj ETQq0106 rgBT (Overlock 1	1.6	0
39	Abstract 1686: Host intrinsic STING is a promising biomarkerfor predicting clinical efficacy of anti-PD-1 inhibitors in lung cancer. , 2021, , .		0
40	The correlation between Crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21167-e21167.	1.6	0
41	Non-invasive analysis of three disease-progression modes in NSCLC patients after taking EGFR-TKIs by next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21168-e21168.	1.6	0
42	Real-world data in clinically non-small cell lung cancer (NSCLC) with Chinese population harboring BRAF gene fusions: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13537-e13537.	1.6	0
43	Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20501-e20501.	1.6	0
44	An EGFR extracellular domain mutation data in the East Asian non-small cell lung cancer populations and response to icotinib: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13000-e13000.	1.6	0
45	Real-world mutational profiling of Chinese non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) uncommon mutations acquired resistant to icotinib using next generation sequencing: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21557-e21557.	1.6	0
46	<i>TP53</i> fusions with next-generation sequencing (NGS) in Chinese non-small cell lung cancer (NSCLC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21742-e21742.	1.6	0
47	APC fusions analysis in Chinese non-small cell lung cancer (NSCLC) using comprehensive NGS panel: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21086-e21086.	1.6	0